Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease

27 Feb 2010

Abstract excerpt

Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by a polyglutamine expansion in huntingtin. There are no treatments that are known to slow the neurodegeneration caused by this mutation. Mutant huntingtin causes disease via a toxic gain-of-function mechanism and has the propensity to aggregate and form intraneuronal inclusions. One therapeutic approach for HD is to enhance the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Genetic Neurodegenerative Diseases
Share to Mitochondrial Function and Pathology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20190273
DOI: 10.1093/hmg/ddq093

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's diseasePMID 20190273Read ↗

Stimulation of mTOR-independent autophagy and mitophagy by rilmenidine exacerbates the phenotype of transgenic TDP-43 mice.Semantic proximity Read ↗

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease.Semantic proximity Read ↗

Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's diseaseSemantic proximity Read ↗

Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies.Semantic proximity Read ↗

Huntington's disease phenotypes are improved via mTORC1 modulation by small molecule therapy.Semantic proximity Read ↗

GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin SignalingSemantic proximity Read ↗

Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's diseaseSemantic proximity Read ↗

Rapamycin alleviates toxicity of different aggregate-prone proteins.Semantic proximity Read ↗

Atg4b-dependent autophagic flux alleviates Huntington's disease progression.Semantic proximity Read ↗

Pharmacological promotion of inclusion formation: A therapeutic approach for Huntington’s and Parkinson’s diseasesSemantic proximity Read ↗

Neferine Attenuates the Protein Level and Toxicity of Mutant Huntingtin in PC-12 Cells via Induction of AutophagySemantic proximity Read ↗

Silmitasertib, an FDA-designated orphan CK2 Inhibitor, ameliorates neuropathology and motor dysfunction in a Huntington’s disease mouse modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.